)
Stereotaxis (STXS) investor relations material
Stereotaxis Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Technology and innovation
Offers unique robotic solutions for minimally invasive endovascular surgery, leveraging robotic magnetic navigation (RMN) for precise catheter control and improved safety and reach in complex anatomies.
GenesisX robot enables rapid installation and compatibility with various x-ray systems, reducing adoption barriers and expanding market opportunities.
Proprietary MAGIC ablation and mapping catheters, along with the Synchrony digital operating room system, drive innovation and recurring revenue.
Acquisition of Robocath and development of EMAGIN vascular devices expand the platform into interventional cardiology and neurointervention.
Digital ecosystem initiatives focus on automation, AI, and enhanced connectivity for operating rooms.
Market presence and growth
Only robotic technology in the $16B+ electrophysiology market, with a total addressable market exceeding $30B.
Over 100 systems installed in more than 20 countries, treating 150,000+ patients globally.
Revenue grew 20% year-over-year to $32M in 2025, with projections for continued growth driven by new product launches and expanded indications.
Multi-specialty platform targets electrophysiology, interventional cardiology, and neurointervention, each representing multi-billion dollar opportunities.
Multiple independent and synergistic drivers support significant revenue acceleration and margin expansion.
Clinical and operational impact
RMN technology delivers 1mm/1° precision, enabling navigation through complex anatomy and reducing patient risk.
Clinical data shows 72% fewer major complications, 36% less radiation exposure, and improved short- and long-term efficacy compared to manual procedures.
Over 500 publications validate clinical value and real-world impact.
Robotic approach enhances physician safety, reduces occupational hazards, and democratizes procedural skill.
Enables advanced care for complex arrhythmias and congenital heart disease, expanding treatment options.
- Recurring revenue surged 270% on new catheter adoption, with profitability targeted for early 2027.STXS
Q2 2026 - Resale registration for 108M+ shares highlights dilution and integration risks after Robocath deal.STXS
Registration filing - Registers 19.9% of shares for resale post-Robocath acquisition; no proceeds to company.STXS
Registration filing - Robotic magnetic navigation and digital innovation drive safer, scalable endovascular surgery worldwide.STXS
Investor presentation - Regulatory wins, new products, and Robocath deal drive optimism for double-digit 2026 growth.STXS
Q1 2026 - Acquisition accelerates robotic leadership in endovascular care, targeting rapid market growth.STXS
M&A announcement - Vote on director elections, auditor ratification, and executive compensation by May 13, 2026.STXS
Proxy filing - Annual meeting to elect directors, ratify auditor, and approve executive compensation.STXS
Proxy filing - Q1 2025 revenue up 9% to $7.5M, driven by recurring revenue and innovation, despite higher net loss.STXS
Q1 2025
Next Stereotaxis earnings date
Next Stereotaxis earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage